Coronavirus disease 2019 vaccination in cancer patients

Q4 Medicine
Z. Tong, Yangang Xing, S. Jiang, X. Li, Mengming Michael Dong
{"title":"Coronavirus disease 2019 vaccination in cancer patients","authors":"Z. Tong, Yangang Xing, S. Jiang, X. Li, Mengming Michael Dong","doi":"10.3760/cma.j.cn114015-20210709-00772","DOIUrl":null,"url":null,"abstract":"Patients with cancer are at high risk for coronavirus disease 2019 (COVID-19). Institutions for disease control and prevention and cancer-related learned societies in many countries recommend prioritizing cancer patients for COVID-19 vaccines. All the COVID-19 vaccines currently approved for emergency use, including inactivated vaccines, mRNA vaccines, recombinant adenovirus vector-based vaccines, and recombinant protein subunit vaccines, can be applied in cancer patients. Cancer patients with stable disease can be vaccinated against COVID-19 at any time, while patients with advanced-stage cancer or undergoing anticancer therapy should decide on the timing of vaccination according to the specific situation such as treatment methods and cancer type, etc.. The benefits of COVID-19 vaccination in cancer patients may outweigh the risks, but the immune response rate may be lower in cancer patients, especially in patients with haematological malignancies, than in healthy individuals. Copyright © 2021 by the Chinese Medical Association.","PeriodicalId":7863,"journal":{"name":"药物不良反应杂志","volume":"35 1","pages":"352-356"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"药物不良反应杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn114015-20210709-00772","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Patients with cancer are at high risk for coronavirus disease 2019 (COVID-19). Institutions for disease control and prevention and cancer-related learned societies in many countries recommend prioritizing cancer patients for COVID-19 vaccines. All the COVID-19 vaccines currently approved for emergency use, including inactivated vaccines, mRNA vaccines, recombinant adenovirus vector-based vaccines, and recombinant protein subunit vaccines, can be applied in cancer patients. Cancer patients with stable disease can be vaccinated against COVID-19 at any time, while patients with advanced-stage cancer or undergoing anticancer therapy should decide on the timing of vaccination according to the specific situation such as treatment methods and cancer type, etc.. The benefits of COVID-19 vaccination in cancer patients may outweigh the risks, but the immune response rate may be lower in cancer patients, especially in patients with haematological malignancies, than in healthy individuals. Copyright © 2021 by the Chinese Medical Association.
癌症患者的2019冠状病毒病疫苗接种
癌症患者是2019冠状病毒病(COVID-19)的高危人群。许多国家的疾病预防控制机构和癌症相关学会建议优先为癌症患者接种COVID-19疫苗。目前批准紧急使用的所有COVID-19疫苗,包括灭活疫苗、mRNA疫苗、重组腺病毒载体疫苗和重组蛋白亚单位疫苗,均可用于癌症患者。病情稳定的癌症患者可随时接种COVID-19疫苗,而晚期癌症患者或正在接受抗癌治疗的患者应根据治疗方法、癌症类型等具体情况决定接种时间。癌症患者接种COVID-19疫苗的益处可能大于风险,但癌症患者,特别是血液系统恶性肿瘤患者的免疫应答率可能低于健康个体。中华医学会版权所有©2021。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
药物不良反应杂志
药物不良反应杂志 Medicine-Pharmacology (medical)
CiteScore
0.20
自引率
0.00%
发文量
3395
期刊介绍:
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信